Testimonials - Multiple Myeloma Research Foundation


Hear what industry leaders are saying about the impact of the MMRF.

  • Anna Barker

    Anna Barker
    Professor, ASU
    “Defining a Cure”

  • Andy Dorner

    Andy Dorner, PhD
    Millennium Pharmaceuticals
    Takeda Oncology Company
    BU School of Medicine
    “Personalized Medicine”

  • Steve Gately

    Steve Gately, PhD
    President & CEO
    Translational Drug Development
    “Precision Medicine”

  • Jonathan Keats

    Jonathan Keats, PhD
    MMRL, TGen
    “Research Success”

  • Daniel Von Hoff

    Dan Von Hoff, MD, FACP
    TGen, Mayo Clinic
    University of Arizona
    Scottsdale Healthcare
    “The MMRF is Faster”

  • Jeffery Trent

    Jeffrey Trent, PhD,

    President, TGen
    Research Director
    “The Immune System”
Matt Damon

Matt Damon, Actor

The MMRF is led by someone who is living with this disease, and she has a severe intolerance for anything that gets in the way of finding a cure. Without a doubt, the MMRF is going to play a huge role in the defeat of Multiple Myeloma.

Julien Adams

Julian Adams, PhD

President, Infinity
Progress is happening so fast because the MMRF is driving everybody to work toward a common goal. The MMRF is a model for how we should be doing things. You’re beginning to see others adopting the MMRF model of saying, “If we work together, we can make a lot more rapid progress.” I think the impact of the MMRF will not just be in multiple myeloma; it’ll ultimately be across many types of disease. I think it’s a pretty great legacy.

Joe Levesque

Joe Leveque, MD

Vice President, U.S. Medical Oncology
Bristol-Myers Squibb

The truth is that most cancers, regardless of their anatomic location, are biologically comparable in that they all use similar evolutionarily conserved pathways to proliferate and survive. The overall progress in the development of treatments and cures is accelerating because we can draw upon knowledge from one cancer to speed success with another. The MMRF has fueled such great progress because they helped bring together the multiple myeloma community. Now, they are helping to do the same for the whole cancer community. There has never been a time of greater hope, promise or accomplishment.

John Carpton

John D. Carpten, PhD

Deputy Director Basic Science, TGen
I think of MMRF as rocket fuel for medical breakthroughs. If there is an idea that has promise, they fuel its launch into an official study. If there is an official study that deserves to go into trial, they propel it towards the clinic. If there is something that merits FDA approval, they thrust into action to move it along months faster than normal. Why? Because there are lives on the line. Real patients who how are hoping for better treatments… Yesterday.

Daniel Von Hoff

Daniel Von Hoff, MD, FACP

Translational Genomics Research Institute (TGen)
In the old days, science was a longshot. Today, we have a much better idea where our medical target is, and many more of the treatments work with precision. In the case of myeloma, mortality has plummeted. Advances have been so dramatic because both bench scientists and clinical investigators are getting the best science to the bedside as rapidly as possible.

Ken Anderson

Kenneth C. Anderson, MD

Dana-Farber Cancer Institute
Harvard Medical School
MMRF Board Member

We need to bring drugs to trial quicker and with less resistance. The MMRF has helped accelerate the whole process for the myeloma community. They are leading the way to champion new drug developments and getting them to patients who need them as quickly as possible.